Cognition Therapeutics, Inc. CGTX
Regular-session close
After hours · Nov 13, 5:36 PM ET
- YTD
- -49.64%
- 1 year
- -55.86%
- Market cap
- 64.65M
- EPS (ttm)
- -0.16
- Shares out
- 41.55M
- Forward P/E
- -0.80
- YTD return
- -49.64%
- 1-year return
- -55.86%
- Volume
- 277.68K
- Avg volume
- 467.67K
- Open
- 0.6854
- Previous close
- 0.6763
- Day's range
- 0.6505 – 0.6999
- 52-week range
- 0.595 – 1.80
- Beta
- 1.33
- Analysts
- Strong Buy
- Price target
- 6.50 (+856.2%)
5D -0.0337 (-4.91%)
Key statistics
- Enterprise value
- -7.19M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -29.72M
- Total cash
- 28.53M
- Total debt
- 809.00K
- Return on equity
- -108.31%
- Short % of float
- 2.94%
- 50-day average
- 0.47888
- 200-day average
- 1.23
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.24 | -0.25 | -0.01 | -4.17% |
| Aug 8, 2024 | Jun 1, 2024 | -0.22 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.22 | -0.18 | +0.04 | +18.18% |
| May 7, 2024 | Mar 1, 2024 | -0.23 | -0.27 | -0.04 | -17.39% |
| May 7, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -0.38 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | B. Riley Securities | up | Neutral | Buy |
| Dec 19, 2024 | Chardan Capital | main | Buy | Buy |
| Dec 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cogrx.com
News
What Makes Cognition Therapeutics (CGTX) a New Buy Stock 
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference 
Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate 
Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints
Your note
Sign in to keep a note on CGTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAGGIANO ANTHONY | Officer | Stock Award(Grant) | Feb 14, 2024 | 141,629 |
| DOYLE JOHN BRENDAN | Chief Financial Officer | Stock Award(Grant) | Feb 14, 2024 | 129,824 |
| FLETCHER AARON G.L. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 6, 2024 | 0 |
| KHATTAR JACK A | Director | Stock Award(Grant) | Jun 6, 2024 | 14,500 |
| KREIS LESLIE W JR | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Nov 7, 2023 | 0 |
| MONIA BRETT P | Director | Stock Award(Grant) | Jun 6, 2024 | 14,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.99% | 1,242,554 | 762.93K | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 1.20% | 500,000 | 307.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.78% | 323,643 | 198.72K | Sep 29, 2024 |
| CM Management, LLC | 0.60% | 250,000 | 153.50K | Sep 29, 2024 |
| American Financial Group Inc. | 0.49% | 205,000 | 125.87K | Sep 29, 2024 |
| UBS Group AG | 0.48% | 197,859 | 121.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.43% | 1,009,905 | 620.08K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.48% | 200,577 | 123.15K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 192,260 | 118.05K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.18% | 76,700 | 47.09K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.17% | 71,610 | 43.97K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 59,268 | 36.39K | Oct 30, 2024 |